Prognostic Implication of KRASG12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands

MLA

Noordhof, Anneloes L., et al. “Prognostic Implication of KRASG12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands.” JTO Clinical and Research Reports, vol. 4, no. 9, Sept. 2023. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2023.100543.

APA

Noordhof, A. L., Swart, E. M., Damhuis, R. A. M., Hendriks, L. E. L., Kunst, P. W. A., Aarts, M. J., & van Geffen, W. H. (2023). Prognostic Implication of KRASG12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands. JTO Clinical and Research Reports, 4(9). https://doi.org/10.1016/j.jtocrr.2023.100543

Chicago

Noordhof, Anneloes L., Esther M. Swart, Ronald A.M. Damhuis, Lizza E.L. Hendriks, Peter W.A. Kunst, Mieke J. Aarts, and Wouter H. van Geffen. 2023. “Prognostic Implication of KRASG12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands.” JTO Clinical and Research Reports 4 (9). doi:10.1016/j.jtocrr.2023.100543.